Brokerages forecast that Chiasma Inc (NASDAQ:CHMA) will post ($0.22) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Chiasma’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.28). Chiasma reported earnings of ($0.32) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 31.3%. The business is expected to report its next quarterly earnings report on Friday, March 13th.
On average, analysts expect that Chiasma will report full year earnings of ($1.03) per share for the current fiscal year, with EPS estimates ranging from ($1.08) to ($0.92). For the next year, analysts anticipate that the firm will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.72) to ($0.67). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Chiasma.
Chiasma (NASDAQ:CHMA) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.01.
A number of equities research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chiasma in a research report on Thursday, November 7th. ValuEngine raised Chiasma from a “sell” rating to a “hold” rating in a report on Wednesday, November 27th. Zacks Investment Research cut Chiasma from a “buy” rating to a “hold” rating in a research report on Monday, October 14th. Finally, Cantor Fitzgerald set a $18.00 target price on Chiasma and gave the stock a “buy” rating in a research note on Friday, September 13th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Chiasma has a consensus rating of “Buy” and an average price target of $12.30.
Shares of Chiasma stock opened at $5.37 on Friday. Chiasma has a 52-week low of $2.11 and a 52-week high of $9.25. The company’s 50-day simple moving average is $5.30 and its 200-day simple moving average is $5.83. The firm has a market cap of $222.29 million, a price-to-earnings ratio of -4.20 and a beta of 1.19.
In related news, Director Roni Mamluk sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $4.94, for a total transaction of $49,400.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at $49,400. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CHMA. Millennium Management LLC purchased a new stake in shares of Chiasma in the 3rd quarter worth about $121,000. Point72 Asset Management L.P. purchased a new position in Chiasma during the 3rd quarter valued at about $8,014,000. California State Teachers Retirement System raised its position in Chiasma by 33.1% during the third quarter. California State Teachers Retirement System now owns 53,381 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 13,284 shares during the last quarter. State Street Corp raised its position in Chiasma by 39.2% during the third quarter. State Street Corp now owns 536,475 shares of the biotechnology company’s stock worth $2,656,000 after acquiring an additional 151,121 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Chiasma by 20.3% in the third quarter. Voya Investment Management LLC now owns 12,713 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 2,149 shares in the last quarter. 74.45% of the stock is owned by hedge funds and other institutional investors.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Article: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.